Visit us at booth #48 to connect with our team and learn more about Decipher Prostate and Decipher Bladder genomic classifiers.

We are excited to announce 15+ abstracts showcasing data on Decipher Prostate, Decipher Bladder, Decipher GRID and the company’s upcoming TrueMRD Test for Muscle-Invasive Bladder Cancer (MIBC).

See the schedule below for dates and times of the presentations.

THURSDAY, FEBRUARY 26, 2026

11:30 AM – 12:45 PM PST

• Abstract #212 | Poster #H6: Investigation of the PORTOS gene expression signature and the benefit of docetaxel in the ECOG-ACRIN E3805 CHAARTED randomized trial.

Presented by: Shuang Zhao, MD, University of Wisconsin-Madison, WI
Level 1, West Hall

11:30 – 12:45 PM PST

• Abstract #224 | Poster #J4: Examination of Decipher prostate genomic classifier in patients with de novo metastatic disease from a large scale real-world clinical and transcriptomic data linkage.

Presented by: Shalini Moningi, MD, Taussig Cancer Institute, Cleveland Clinic, OH
Level 1, West Hall

11:30 – 12:45 PM PST

• Abstract #350 | Poster #L4: Association between genomic classifier scores and initial management of localized prostate cancer in a population-based cohort in the United States.

Presented by: Michael S. Leapman, MD, MHS, Yale School of Medicine, CT
Level 1, West Hall

11:30 – 12:45 PM PST

• Abstract #382 | Poster #M10: Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.

Presented by: Xiaolei Shi, MD, PhD, University of Maryland School of Medicine, MD
Level 1, West Hall

11:30 – 12:45 PM PST

• Abstract #386 | Poster #M14: Genomic risk classifier performance in PET-guided post-prostatectomy patients: Secondary analysis of a randomized trial.

Presented by: Ashesh B. Jani, MD, Emory University, GA
Level 1, West Hall

11:30 – 12:45 PM PST

• Abstract #392 | Poster #M20: FAP+FN1+CAV1+ cancer-associated fibroblast subtype and its association with aggressive behavior in localized prostate cancer.

Presented by: Mohammed Shahait, MBBS, UC Irvine Medical Center, CA
Level 1, West Hall

11:30 – 12:45 PM PST

• Abstract #396 | Poster #M24: Transcriptomic characterization of prostate cancer in patients with HIV infection.

Presented by: Michael S. Leapman, MD, MHS, Yale School of Medicine, CT
Level 1, West Hall

11:30 – 12:45 PM PST

• Abstract #390 | Poster #M18: PAM50 intrinsic subtyping and Decipher genomic classifier in biochemically recurrent prostate cancer after prostatectomy: Implications for ADT selection.

Presented by: Jonathan D. Tward, MD, PhD, University of Utah, UT
Level 1, West Hall

11:30 – 12:45 PM PST

• Abstract #402 | Poster #N4: Integrating genomic prognostic and hallmark signatures from Decipher GRID to predict adverse outcomes in men on active surveillance for prostate cancer.

Presented by: Kevin Shee, MD, PhD, BA, University of California, San Francisco, CA
Level 1, West Hall

FRIDAY, FEBRUARY 27, 2026

4:00 – 4:45 PM PST

• Abstract #737: Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in pts with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444).

Presented by: Jonathan F Anker, MD, PhD, Mount Sinai Tisch Cancer Center, NY
Level 3, Ballroom | Rapid Oral Presentation

11:30 – 12:45 PM PST

• Abstract #769 | Poster #H1: Neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC): SURE-02 primary analysis and biomarker results.

Presented by: Andrea Necchi, MD, Vita-Salute San Raffaele University, Italy
Level 1, West Hall

11:30 – 12:45 PM PST

• Abstract #841 | Poster #K21: A composite biomarker approach to withhold neoadjuvant chemotherapy in select muscle-invasive bladder cancer patients.

Presented by: Joep De Jong, MD, PhD, Erasmus University Medical Center, The Netherlands 
Level 1, West Hall

11:30 – 12:45 PM PST 

• Abstract #843 | Poster #K23: Association of non-luminal subtype with overall survival in high-risk non-muscle invasive bladder cancer patients: Biomarker results from the Bladder Cancer Prognosis Programme.

Presented by: Joep De Jong, MD, PhD, Erasmus University Medical Center, The Netherlands
Level 1, West Hall

11:30 – 12:45 PM PST

• Abstract #845 | Poster #K25: Association between non-luminal molecular subtypes and complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo and BLASST-01 phase 2 clinical trials. 

Presented by: Joep De Jong, MD, PhD, Erasmus University Medical Center, The Netherlands 
Level 1, West Hall 

11:30 – 12:45 PM PST 

• Abstract #851 | Poster #L5: Examining the impact of TGF-ß activity on fibroblast infiltration and immune exclusion in MIBC. 

Presented by: Shilpa Gupta, MD, Taussig Cancer Institute, Cleveland Clinic, OH
Level 1, West Hall